Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.
Actively Recruiting
Researchers are investigating how exercise might affect treatment outcomes for patients with metastatic colorectal cancer receiving chemotherapy. The study focuses on whether exercise can prevent changes to chemotherapy doses caused by toxicity, improve immune function, and enhance progression-free survival. It also seeks to identify the best type and amount of exercise for these benefits. This is a randomized, multi-arm trial using a Bayesian adaptive design to efficiently compare different exercise programs while minimizing patient exposure to less effective options. Participants are randomly assigned to one of three groups a resistance and continuous aerobic exercise group, an aerobic interval and continuous aerobic exercise group, or a usual care group. Those in the exercise groups engage in supervised moderate-to-high intensity sessions twice a week, plus a third session at home. The exercise includes activities like walking, cycling, and resistance exercises targeting large muscle groups. The usual care group receives standard treatment with exercise guidelines provided. The study uses several interim analyses to potentially stop less effective exercise arms early. During the study, participants undergo regular assessments including chemotherapy dose modifications, progression-free survival, immune cell function, hospitalization, treatment-related toxicities, fitness, muscle strength and mass, quality of life, fatigue, resilience, empowerment, and physical activity levels. These measures are taken from baseline through multiple chemotherapy cycles over several months, with outcomes monitored for up to two years. The study aims to better understand how exercise affects treatment effectiveness and patient well-being in metastatic colorectal cancer.
Actively Recruiting
This research aims to compare the effects of oral anticoagulation versus no anticoagulation in patients aged 55 and older who have had recent episodes of transient atrial fibrillation triggered by stress and have additional factors that increase their risk of stroke. The study is a multinational, investigator-initiated, prospective, randomized, open-label trial evaluating the impact of non-vitamin K oral anticoagulants NOACs on preventing stroke and other serious cardiovascular events. Participants will be randomly assigned to either receive one of several NOACs, such as edoxaban, apixaban, dabigatran, or rivaroxaban, prescribed by their physician for the duration of the follow-up, or to a control group that will not receive anticoagulants unless medically indicated during the study. The choice of specific NOAC and dose adjustments are determined by the prescribing doctor. The study excludes patients with certain conditions like chronic atrial fibrillation, severe kidney or liver disease, recent cardiac surgery, or bleeding risks. During the study, participants will be monitored for up to 24 months to assess the occurrence of non-hemorrhagic stroke, systemic embolism, vascular mortality, myocardial infarction, peripheral arterial thrombosis, amputation, and venous thromboembolism. Regular follow-up will include evaluation of these outcomes to measure the effectiveness and safety of anticoagulation compared to no anticoagulation. Participants will provide informed consent and remain under medical supervision throughout the trial.
Actively Recruiting
Researchers are evaluating chemotherapy dosing strategies in older patients aged 70 years and above who have metastatic colorectal cancer and are eligible for first-line palliative chemotherapy. This phase III randomized controlled trial aims to compare upfront dose-reduced chemotherapy with standard full-dose chemotherapy, focusing on progression-free survival PFS. Patients are assessed using the Geriatric 8 G8 questionnaire to determine their risk of chemotherapy toxicity, which guides treatment assignment. The study seeks to balance treatment effectiveness with minimizing toxicity, hospital admissions, and maintaining quality of life QoL and physical functioning. Participants classified as low risk for toxicity G8 score 15 or higher are randomized to receive either doublet chemotherapy a fluoropyrimidine combined with oxaliplatin at full dose or with a 25% dose reduction upfront. Those at high risk G8 score 14 or lower or judged high risk by their oncologist receive fluoropyrimidine monotherapy either at full dose or with a 25% dose reduction. The study also allows the addition of targeted treatments like bevacizumab or EGFR inhibitors. Dose adjustments are made for patients with moderate kidney impairment. Chemotherapy is given orally or intravenously on schedules varying between every two and three weeks, depending on the regimen. Participants will be closely monitored throughout treatment, with assessments including radiological or clinical evaluations for disease progression, quality of life and physical functioning questionnaires at 1, 3, 6, and 12 months, and tracking of chemotherapy toxicity, overall survival, treatment cycles, dose changes, hospital admissions, and cumulative drug dosage. Safety and cost-effectiveness will also be evaluated over an average study duration of eight months and up to one year for some outcomes. The study plans to include 587 patients and will continue until December 2028.
Actively Recruiting
This research aims to support veterans who experience post-traumatic stress disorder PTSD along with difficulties in managing emotions, aggression, and related challenges. The study focuses on veterans for whom previous treatments have not been effective, offering a specialized aftercare program to help maintain and apply new coping skills over time. The program builds on an earlier 12-week inpatient therapy designed specifically for veterans with complex psychiatric symptoms after active duty missions. Participants will receive hybrid dialectical behavior therapy DBT, which includes face-to-face group skill sessions, individual online sessions, and online homework assignments. All participants follow the same therapy program, but the timing between the initial baseline assessment and the start of the therapy varies randomly. This approach aims to consolidate and reinforce therapy skills learned during prior inpatient treatment. Throughout the study, participants will be monitored from baseline through a follow-up period lasting between 12 to 17 months. Researchers will assess PTSD symptoms and difficulties in emotion regulation using standardized checklists and scales. The study includes ongoing monitoring of participant progress and safety, with the goal of reducing symptom recurrence and improving long-term outcomes for veterans.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating treatment approaches for cryptoglandular anal fistulas, a painful and recurring condition that can cause discharge and require a prolonged treatment course. The trial compares two common strategies for patients with a single-tract mid-high or high cryptoglandular anal fistula one involving loose seton placement before surgery and one with direct sphincter-preserving surgery without prior seton. The study aims to determine if skipping the seton placement is not worse in terms of fistula healing 26 weeks after surgery. Participants are randomly assigned to either receive a loose seton placed for about 8 weeks followed by sphincter-preserving surgery, or to have the surgery directly without seton placement. The specific surgical technique is chosen by the surgeon based on local practice and fistula anatomy and may include methods like advancement flap, ligation of the intersphincteric fistula tract, or laser ablation. The study uses a randomized controlled design across multiple centers to compare these two approaches. During the study, participants complete questionnaires measuring quality of life, pain, continence, and anorectal symptoms at several time points up to 12 months. Clinical outcomes like healing, complications, and re-interventions are recorded. The main outcome is successful fistula closure 26 weeks after surgery, confirmed by physical exam and imaging if needed. The study also assesses return to work, healthcare use, and societal costs. Data are securely collected and analyzed to determine if omitting seton placement can reduce treatment burden and costs while maintaining patient outcomes.
Actively Recruiting
Researchers are investigating whether dexrazoxane can prevent heart damage caused by anthracycline chemotherapy in patients with diffuse large B-cell lymphoma DLBCL. This condition, known as anthracycline-induced cardiac dysfunction AICD, can lead to irreversible heart muscle damage and heart failure. Patients with DLBCL are at higher risk of AICD due to their treatment regimen and longer survival, making prevention of heart damage important. This is a national phase III randomized controlled trial conducted across multiple hospitals in the Netherlands. Participants will receive six cycles of R-CHOP21 chemotherapy, which includes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. They will be randomly assigned to either receive dexrazoxane intravenously before doxorubicin infusion or to receive standard treatment without dexrazoxane. Some patients with double hit lymphoma may receive lenalidomide as part of their regimen. The trial does not use placebo due to the nature of dexrazoxane. Cardiac function will be monitored using echocardiography before treatment and at 4 and 12 months after treatment starts. Participants will undergo heart function tests, metabolic remission assessments, survival evaluations, blood biomarker tests, and quality of life questionnaires during the study. The main outcome is the occurrence of significant heart function decline within 12 months. The study will also assess whether dexrazoxane affects cancer treatment effectiveness. Participants will be followed for at least one year to monitor heart health and cancer status, with regular visits for evaluations and treatment administration.
Actively Recruiting
Researchers are investigating how various factors beyond tumor stage, such as biochemical, histopathological, genomic, environmental, and clinical characteristics, affect the outcomes of patients diagnosed with colorectal cancer CRC, small bowel cancer, and anal cancer. This observational study aims to collect detailed information from diagnosis through long-term follow-up to better understand prognosis and treatment effects in both early and late-stage cancers. The study addresses the gap between clinical trial populations and real-world patients by including a broader patient group treated in general practice. Participants will be followed prospectively from their initial diagnosis until death. Data collection includes medical history, clinical parameters, imaging, pathology, tumor details, treatments, hospital stays, interventions, and adverse events. With separate consent, patient-reported quality of life and work ability information will also be gathered. Additionally, biological samples obtained during routine care may be collected for further observational and molecular research. This cohort serves as a platform for evaluating new interventions through a Trials within Cohorts TwiCs design. Throughout up to ten years of follow-up, participants will undergo assessments of progression-free survival, disease-free survival, overall survival, and serious adverse events. Quality of life and work ability are assessed at intervals of 3, 6, 12, 24, 36, and 48 months. This extensive data collection supports a wide range of research aims including prognostic studies, molecular analyses, comparisons of new treatments, and health policy evaluations. The study provides a comprehensive view of treatment outcomes and patient experiences in everyday clinical settings.
Actively Recruiting
This research investigates a treatment approach for low-risk breast cancer in female patients aged 50 and above. The study evaluates the effects of a single-dose preoperative partial breast radiotherapy guided by MRI, aiming to measure the rate of complete tumor disappearance at the time of surgery, which occurs between six and twelve months after radiotherapy. Researchers will also monitor tumor response through MRI scans and blood and tumor tissue markers to predict this outcome. Patients receive a single dose of radiotherapy targeting the tumor area, with doses of 20Gy to the gross tumor volume and 15Gy to the clinical tumor volume. Surgery to conserve the breast is planned around 12 months after radiotherapy if MRI shows a complete response. If MRI indicates an incomplete response or disease progression, surgery may be moved earlier, around six months or sooner. During the months between radiotherapy and surgery, MRI scans occur every three months to monitor tumor response. Participants will be assessed regularly using MRI scans and various blood and tissue tests to follow tumor changes and treatment effects. After surgery, patients will be followed for up to 10 years to evaluate cancer outcomes, side effects, cosmetic results, and quality of life. The primary measure is the complete pathological response at 12 months post-radiotherapy, with secondary measures including radiologic response, adverse events, quality of life, cosmetic outcomes, recurrence rates, survival, and biomarkers related to radiotherapy effects.
Actively Recruiting
Researchers are investigating the effects of five different dialysis treatments on microcirculation and sequestered sodium content in adults with end-stage kidney disease ESKD undergoing hemodialysis or hemodiafiltration. This randomized crossover trial aims to understand how dialysis mode and dialysate sodium concentration affect these factors, which may relate to vascular function and patient survival. The study explores whether treatments like high-volume hemodiafiltration improve these conditions compared to standard hemodialysis. Participants will receive various dialysis treatments in random order, including high-flux hemodialysis and high-volume hemodiafiltration with different dialysate sodium concentrations and an isolated ultrafiltration session followed by hemodialysis. Each treatment mode is studied over 4-week periods, focusing on sodium balance and convection volume during dialysis sessions. The trial compares five distinct combinations of dialysis modes and dialysate sodium levels to assess their impact. During the study, participants will have their sequestered salt content measured in muscle and skin every 4 weeks before the last dialysis session of each treatment period, up to 20 weeks total. Skin microcirculation and blood pressure changes during dialysis are also monitored closely. Various blood and inflammatory markers are assessed before and after dialysis sessions. Quality of life and symptom scales are evaluated regularly, with continuous safety and treatment effect monitoring throughout the trial.